Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.43 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14353010 | 0.80 | ALDH2 (1.00) | ALDH2MAPT | |
| SCHEMBL28807425 | 0.77 | MAOA (0.55) | HPGDKDM4EGLAL3MBTL1AKR1B1 | |
| SCHEMBL14352803 | 0.77 | ALDH2 (0.62) | ALDH2ALDH1A1MAPT | |
| SCHEMBL18699124 | 0.76 | ALDH2 (0.50) | ALDH2HPGDKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL26922366 | 0.76 | ALDH2 (0.57) | ALDH2HPGDL3MBTL1ALDH1A1MAPT | |
| SCHEMBL25300444 | 0.72 | ALDH2 (0.46) | ALDH2HPGDKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL14352988 | 0.72 | ALDH2 (0.46) | ALDH2HPGDKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL13744662 | 0.72 | TP53 (0.50) | HPGDL3MBTL1AKR1B1ALDH1A1LMNA | |
| SCHEMBL26921983 | 0.71 | KMT2A (0.45) | ALDH2AKR1B1ALDH1A1NPC1RAB9A | |
| SCHEMBL26922558 | 0.70 | ALDH2 (0.61) | ALDH2L3MBTL1ALDH1A1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180338989-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-11-29 | — | — | US | disclosed |
| US-9987295-B2 | Compounds for the treatment of addiction | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987295-B2 | Compounds for the treatment of addiction | AMYGDALA NEUROSCIENCES, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-2993170-B1 | N-[4-(2-OXO-1,2-DIHYDRO-PYRIDIN-4-YL)-BENZYL]-BENZAMIDE DERIVATIVES AS ALDH-2 INHIBITORS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2993170-B1 | N-[4-(2-OXO-1,2-DIHYDRO-PYRIDIN-4-YL)-BENZYL]-BENZAMIDE DERIVATIVES AS ALDH-2 INHIBITORS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | AMYGDALA NEUROSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9610299-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9610299-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-8558001-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8558001-B2 | Compounds for the treatment of addiction | GILEAD SCIENCES, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2013006400-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013006400-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | GILEAD SCIENCES, INC. (US) | 2013-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338989-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885HPGD 369/4885KDM4E 2510/4885 |
| US-20130203704-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885HPGD 369/4885KDM4E 2510/4885 |
| US-20130005689-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885HPGD 369/4885KDM4E 2510/4885 |
| US-20170266210-A1 | COMPOUNDS FOR THE TREATMENT OF ADDICTION | OPRK1, OPRM1, OPRD1 | ALDH2 393/4885HPGD 369/4885KDM4E 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.